Patients with hepatitis C who are successfully treated with direct-acting antiviral agents experience a dramatic reduction in their risk for liver cancer, new data show. However, the decrease is much lower for those diagnosed with cirrhosis before starting a DAA.
The risk for liver cancer after a sustained virologic response (SVR) is achieved is still above zero. As a result, the new data point to the need for cancer surveillance in at least some patients successfully treated for HCV, said